Keyphrases
Alpha-1 Antitrypsin
100%
Alpha-1 Antitrypsin Deficiency
100%
Augmentation Therapy
100%
Carbon Dioxide
20%
Chronic Obstructive Pulmonary Disease
40%
Clinical Effect
20%
Cochrane Central Register of Controlled Trials
20%
Computed Tomography
20%
Confidence Interval
80%
Deficiency Diseases
100%
Ex-smokers
20%
Financial Conflicts of Interest
20%
Forced Expiratory Volume in 1 Second (FEV1)
20%
Genetic Variants
20%
High Risk
20%
Hospital Admission
40%
Inherited Disorders
20%
Lung Density
20%
Lung Disease
100%
Lung Infection
40%
Mean Group
20%
Mortality Data
20%
Never-smokers
20%
Placebo
20%
Placebo Groups
100%
PubMed
20%
Quality of Life
40%
Randomized Trial
20%
Review Authors
20%
Review Update
20%
Risk of Bias
20%
Serious Adverse Events
40%
Sparse Data
20%
Standardized Mean Difference
20%
Treatment Group
100%
Nursing and Health Professions
Adverse Event
33%
Alpha 1 Antitrypsin
100%
Alpha 1 Antitrypsin Deficiency
100%
Carbon Monoxide
16%
Cochrane Library
16%
Computer Assisted Tomography
16%
Confidence Interval
66%
Diseases
33%
Forced Expiratory Volume
16%
Lung Disease
100%
Lung Infection
33%
Medline
16%
Obstructive Lung Disease
33%
Placebo
100%
Quality of Life
33%
Treatment Group
83%
Medicine and Dentistry
Adverse Event
33%
Alpha 1 Antitrypsin
100%
Alpha 1-Antitrypsin Deficiency
100%
Carbon Monoxide
16%
Chronic Obstructive Pulmonary Disease
33%
Computer Assisted Tomography
16%
Diseases
33%
Forced Expiratory Volume
16%
Lung
16%
Lung Infection
33%
Placebo
100%
Quality of Life
33%
Silo-Filler's Disease
100%
Smoke
16%
Smoking
16%
Treatment Group
83%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Alpha 1 Antitrypsin
100%
Alpha 1 Antitrypsin Deficiency
100%
Carbon Monoxide
16%
Chronic Obstructive Lung Disease
33%
Diseases
33%
Lung Disease
100%
Lung Infection
33%
Placebo
100%
Treatment Group
83%